Blood Pressure-Lowering Peptides Discovered in Porcine Liver and Placenta

Four novel peptides from porcine liver and placenta hydrolysates inhibit ACE, the enzyme targeted by blood pressure medications, with FWG and MFLG showing the strongest activity.

Pearman, Nicholas A et al.·Molecules (Basel·2025·very-lowin-vitro
RPEP-12997In Vitrovery-low2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in-vitro
Evidence
very-low
Sample
N=Not applicable (in vitro)
Participants
Not applicable (peptide chemistry)

What This Study Found

Four peptides from porcine liver and placenta (FWG, MFLG, SDPPLVFVG, FFNDA) demonstrated ACE-inhibitory activity, with placenta hydrolysate outperforming both liver hydrolysate and individual synthetic peptides.

Key Numbers

Four peptides identified: FWG, MFLG, SDPPLVFVG, FFNDA. FWG and MFLG more potent than SDPPLVFVG and FFNDA. IC50 values comparable to porcine muscle-derived peptides. Less potent than captopril.

How They Did This

In vitro study using papain digestion of porcine tissues, in silico enzymatic cleavage prediction, HPLC-MS/MS identification, peptide synthesis, and ACE inhibition assays.

Why This Research Matters

Finding natural ACE-inhibiting peptides from food-grade animal byproducts could lead to functional foods or nutraceuticals for blood pressure management, potentially with fewer side effects than pharmaceutical ACE inhibitors.

The Bigger Picture

This work contributes to the growing field of food-derived bioactive peptides that could offer natural approaches to cardiovascular health management, adding value to animal byproducts that are often discarded.

What This Study Doesn't Tell Us

In vitro ACE inhibition only — bioavailability, stability in the digestive system, and actual blood pressure effects in living organisms have not been tested.

Questions This Raises

  • ?Will these peptides survive digestion and remain active when consumed orally?
  • ?How do these natural ACE inhibitors compare in potency to pharmaceutical drugs like captopril?

Trust & Context

Key Stat:
FWG and MFLG most potent Two short peptides from porcine tissue showed the strongest ACE inhibition among four candidates tested
Evidence Grade:
In vitro laboratory study. ACE inhibition in a test tube does not guarantee blood pressure reduction in humans — animal studies and clinical trials would be needed.
Study Age:
Published in 2025, contributing to the growing evidence base for food-derived bioactive peptides.
Original Title:
Angiotensin-Converting Enzyme (ACE)-Inhibitor Activity of Novel Peptides Derived from Porcine Liver and Placenta.
Published In:
Molecules (Basel, Switzerland), 30(3) (2025)
Database ID:
RPEP-12997

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What is ACE and why is inhibiting it important?

ACE (angiotensin-converting enzyme) produces a hormone that constricts blood vessels and raises blood pressure. Blocking ACE is the mechanism behind common blood pressure drugs. Finding natural peptides that do the same could offer food-based alternatives.

Could eating pork liver lower blood pressure?

Not directly from this study. While the peptides were extracted from porcine tissue, they were concentrated and purified in a lab. Whether eating these foods would deliver enough active peptide to affect blood pressure is unknown.

Read More on RethinkPeptides

Cite This Study

RPEP-12997·https://rethinkpeptides.com/research/RPEP-12997

APA

Pearman, Nicholas A; Morris, Gordon A; Smith, Alan M. (2025). Angiotensin-Converting Enzyme (ACE)-Inhibitor Activity of Novel Peptides Derived from Porcine Liver and Placenta.. Molecules (Basel, Switzerland), 30(3). https://doi.org/10.3390/molecules30030754

MLA

Pearman, Nicholas A, et al. "Angiotensin-Converting Enzyme (ACE)-Inhibitor Activity of Novel Peptides Derived from Porcine Liver and Placenta.." Molecules (Basel, 2025. https://doi.org/10.3390/molecules30030754

RethinkPeptides

RethinkPeptides Research Database. "Angiotensin-Converting Enzyme (ACE)-Inhibitor Activity of No..." RPEP-12997. Retrieved from https://rethinkpeptides.com/research/pearman-2025-angiotensinconverting-enzyme-aceinhibitor-activity

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.